Hirai H, Hirano N, Yazaki Y
Third Dept. of Internal Medicine Faculty of Medicine, University of Tokyo.
Gan To Kagaku Ryoho. 1991 Jun;18(7):1090-7.
N-ras oncogenes activated by point mutation have been frequently detected in various types of human leukemias. Analysis of a large number of leukemias revealed that activated N-ras oncogenes were observed preferentially in AML, AMoL, T-ALL and Null-ALL but rarely in CML and B-cell leukemia. These results suggest that N-ras oncogene plays an important role in human leukemogenesis. Activated N-ras oncogenes were also detected in myelodysplastic syndrome (MDS) that is considered to be a preleukemic disease. MDS patients bearing an activated N-ras oncogene frequently showed leukemic progression of the disease, suggesting that an activated N-ras oncogene can be a critical factor for prognosis of MDS patients. Thus, detection of an activated N-ras oncogene is useful for diagnosis, prognostic evaluation and therapeutic decision. Recently, we demonstrated that detection of the minimal residual disease by analysis of N-ras oncogene can lead to improvement of the remission rate in leukemias. Moreover, we made it possible to screen N-ras oncogene by a sensitive non-radioactive method. Our research procedure seems to be a good model for clinical application of the molecular biological technique.
通过点突变激活的N-ras癌基因在各种类型的人类白血病中经常被检测到。对大量白血病的分析表明，激活的N-ras癌基因在急性髓系白血病（AML）、急性单核细胞白血病（AMoL）、T细胞急性淋巴细胞白血病（T-ALL）和裸细胞急性淋巴细胞白血病（Null-ALL）中优先被观察到，但在慢性粒细胞白血病（CML）和B细胞白血病中很少见。这些结果表明，N-ras癌基因在人类白血病发生中起重要作用。在被认为是白血病前期疾病的骨髓增生异常综合征（MDS）中也检测到了激活的N-ras癌基因。携带激活的N-ras癌基因的MDS患者经常出现疾病的白血病进展，这表明激活的N-ras癌基因可能是MDS患者预后的关键因素。因此，检测激活的N-ras癌基因对诊断、预后评估和治疗决策是有用的。最近，我们证明通过分析N-ras癌基因检测微小残留病可以提高白血病的缓解率。此外，我们能够通过一种灵敏的非放射性方法筛选N-ras癌基因。我们的研究程序似乎是分子生物学技术临床应用的一个良好模型。
